

# The Predictive Value of LCN2 (NGAL) in Renal Transplant Recipients

Peter Hamar<sup>1,2\*</sup>

<sup>1</sup>Department of Dentistry, Oral and Maxillofacial Surgery and Translational Medicine Institute, University of Pecs, Hungary

<sup>2</sup>Institutes of Clinical Experimental Research and Pathophysiology, Semmelweis University, Hungary

\*Corresponding author: Peter Hamar, Department of Dentistry, Oral and Maxillofacial Surgery and Translational Medicine Institute, University of Pecs, Hungary, Tel: +36-20-825-9751; E-mail: hampet@net.sote.hu

Received date: November 10, 2017; Accepted date: November 10, 2017; Published date: November 17, 2017.

Copyright: © 2017 Hamar P. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

## Editorial

Retention parameters (creatinine, urea) signal kidney injury only after a certain degree of irreversible damage. Lipocalin-2 (LCN2), originally described as neutrophil gelatinase associated lipocalin (NGAL)-has been established as an acute kidney injury (AKI) biomarker as it is produced by tubular epithelial cells after hypoxic or other injury [1]. LCN2 may be a more sensitive and thus, an earlier marker of incipient injury than creatinine [2]. Urinary LCN2 was predictive for the need to (re)initiate dialysis after intensive care unit admission [3].

LCN2 transports small hydrophobic molecules such as lipids and steroids [4] and plays a bacteriostatic role by sequestering iron-containing siderophores. Mice lacking LCN2 are more susceptible to bacterial infection [5]. LCN2 as a kidney injury marker is not specific as it is an acute phase protein [6] and its major source is the liver in mice [7] and humans [8]. Furthermore, it can be a product of injured epithelial cells other than the renal tubular epithelium [9]. Thus, urinary excretion (U) or U to plasma (P) ratio may be more informative for kidney injury than plasma levels [10]. However, there is some disagreement whether urinary or plasma NGAL is a better AKI marker [11]. There has been a number of attempts to increase the sensitivity/specificity of LCN2 to detect AKI such as repeated measurements [4,11,12] or normalization of urinary to plasma (U/P) NGAL [8].

Although LCN2 has been established as an AKI marker, the predictive or prognostic value of LCN2 for long term outcome in renal transplant recipients is not clear. Renal transplantation is always accompanied by severe AKI. Since the recognition of severe AKI-induced chronic kidney disease (CKD) [13] AKI markers may have a long-term prognostic relevance. Few papers have investigated LCN2 in this respect. Plasma LCN2 >50 ng/mL was associated with higher frequency of delayed graft function (DGF) [14] and rejection rates after transplantation [4,15]. High serum or urinary NGAL after transplantation was predictive of graft loss at one year [4]. LCN2 is an early and sensitive marker of graft dysfunction due to hypoxia, rejection, calcineurin inhibitor toxicity, occlusion of the urine outflow or infection [4]. LCN2 may not discriminate these causes of tubular injury; however, all of these may significantly shorten graft survival. Thus, LCN2 may predict long term outcome. Although few studies investigated LCN2 in chronic renal fibrosis induced by diabetic nephropathy [16] or primary glomerulonephritis [17], there is very limited data on chronic allograft nephropathy (CAN) or interstitial fibrosis and tubular atrophy (IFTA). A biomarker panel including  $\beta$ 2-microglobulin, LCN2, clusterin and KIM-1 in the urine was able to detect CAN [18] and a recent study concluded that LCN2 may predict both DGF and CAN [19].

In conclusion, LCN2 may be a reliable prognostic marker for long term graft outcome, but the possible prognostic value of LCN2 has not been exploited yet.

## References

1. Ramirez-Sandoval JC, Herrington W, Morales-Buenrostro LE (2015) Neutrophil gelatinase-associated lipocalin in kidney transplantation. *Transplant Rev* 29: 139-144.
2. Shang W, Wang Z (2017) The Update of NGAL in Acute Kidney Injury. *Curr Protein Pept Sci* 18: 1211-1217.
3. Albeladi FI, Algethamy HM (2017) Urinary Neutrophil Gelatinase-Associated Lipocalin as a Predictor of Acute Kidney Injury, Severe Kidney Injury, and the Need for Renal Replacement Therapy in the Intensive Care Unit. *Nephron Extra* 7: 62-77.
4. Schiefner A, Skerra A (2015) The menagerie of human lipocalins: a natural protein scaffold for molecular recognition of physiological compounds. *Acc Chem Res* 48: 976-85.
5. Nasioudis D, Witkin SS (2015) Neutrophil gelatinase-associated lipocalin and innate immune responses to bacterial infections. *Med Microbiol Immunol* 204: 471-479.
6. Sultan S, Pascucci M, Ahmad S, Malik IA, Bianchi A, et al. (2012) LIPOCALIN-2 is a major acute-phase protein in a rat and mouse model of sterile abscess. *Shock* 37: 191-196.
7. Xu MJ, Feng D, Wu H, Wang H, Chan Y, et al. (2015) Liver is the major source of elevated serum lipocalin-2 levels after bacterial infection or partial hepatectomy: a critical role for IL-6/STAT3. *Hepatology* 61: 692-702.
8. Yoshikawa K, Iwasa M, Eguchi A, Kojima S, Yoshizawa N, et al. (2017) Neutrophil gelatinase-associated lipocalin level is a prognostic factor for survival in rat and human chronic liver diseases. *Hepatology Commun* 1: 946-956.
9. Devarajan P (2010) Neutrophil gelatinase-associated lipocalin: a promising biomarker for human acute kidney injury. *Biomark Med* 4: 265-280.
10. Kaucsar T, Godo M, Revesz C, Kovacs M, Mocsai A, et al. (2016) Urine/Plasma Neutrophil Gelatinase Associated Lipocalin Ratio Is a Sensitive and Specific Marker of Subclinical Acute Kidney Injury in Mice. *PLoS One* 11: e0148043.
11. Matsa R, Ashley E, Sharma V, Walden AP, Keating L (2014) Plasma and urine neutrophil gelatinase-associated lipocalin in the diagnosis of new onset acute kidney injury in critically ill patients. *Crit Care* 18: R137.
12. Mahmoodpoor A, Hamishehkar H, Fattahi V, Sanaie S, Arora P, et al. (2017) Urinary versus plasma neutrophil gelatinase-associated lipocalin (NGAL) as a predictor of mortality for acute kidney injury in intensive care unit patients. *J Clin Anesth* 44: 12-17.
13. Lo LJ, Go AS, Chertow GM, McCulloch CE, Fan D, et al. (2009) Dialysis-requiring acute renal failure increases the risk of progressive chronic kidney disease. *Kidney Int* 76: 893-899.
14. Lee EY, Kim MS, Park Y, Kim HS (2012) Serum neutrophil gelatinase-associated lipocalin and interleukin-18 as predictive biomarkers for delayed graft function after kidney transplantation. *J Clin Lab Anal* 26: 295-301.
15. Field M, Lowe D, Cobbold M, Higgins R, Briggs D, et al. (2014) The use of NGAL and IP-10 in the prediction of early acute rejection in highly

- 
- sensitized patients following HLA-incompatible renal transplantation. *Transpl Int* 27: 362-370.
16. Hwang S, Park J, Kim J, Jang HR, Kwon GY, et al. (2017) Tissue expression of tubular injury markers is associated with renal function decline in diabetic nephropathy. *J Diabetes Complications* 31: 1704-1709.
  17. Lertrit A, Worawichawong S, Vanavanan S, Chittamma A, Muntham D, et al. (2016) Independent associations of urine neutrophil gelatinase-associated lipocalin and serum uric acid with interstitial fibrosis and tubular atrophy in primary glomerulonephritis. *Int J Nephrol Renovasc Dis* 9: 111-118.
  18. Cassidy H, Slyne J, O'Kelly P, Traynor C, Conlon PJ, et al. (2015) Urinary biomarkers of chronic allograft nephropathy. *Proteomics Clin Appl* 9: 574-585.
  19. Lacquaniti A, Caccamo C, Salis P, Chirico V, Buemi A, et al. (2016) Delayed graft function and chronic allograft nephropathy: diagnostic and prognostic role of neutrophil gelatinase-associated lipocalin. *Biomarkers* 21: 371-378.